What question did this study set out to answer?

This research aims to assess population-based outcomes and patterns of care based on estrogen receptor expression levels in HER2-negative breast cancer.

February 19, 2026Clinical Cancer Research

Abstract PS2-06-15: Population-based outcomes and patterns of care for patients with stage I-III, HER2-negative breast cancer, by estrogen receptor expression levels: a high-resolution study

View Full Paper

Ask AI

Bookmark

This research aims to assess population-based outcomes and patterns of care based on estrogen receptor expression levels in HER2-negative breast cancer.
Analyzed a large cohort of women with stage I-III HER2-negative breast cancer from a tumor registry.
Stratified patients by estrogen receptor expression categories: TNBC, ER-low, ER 10-49%, and ER ≥50%.
Collected patient data on surgery, chemotherapy, and endocrine therapy from cancer registry and claims.
Estimated cancer-specific survival rates by ER category up to six years post-diagnosis.
3,771 patients were diagnosed with stage I-III HER2-negative breast cancer between 2017 and 2021.
Three-year cancer-specific survival was 90.2% for TNBC, 90.5% for ER-low, 94.6% for ER 10-49%, and 98.4% for ER ≥50%.
At six years, survival rates were 85% for TNBC, stabilized around 90% for ER-low and ER 10-49%, and above 95% for ER ≥50%.
Only 23.7% of ER-low patients received endocrine therapy, suggesting a potential benefit over time.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Population-based outcomes reveal survival differences by estrogen receptor levels in HER2-negative breast cancer, indicating treatment implications.

Cite This Study

Girardi et al. (2026) studied this question.

synapsesocial.com/papers/6996a869ecb39a600b3ef16c https://doi.org/10.1158/1557-3265.sabcs25-ps2-06-15

View Full Paper

Ask AI

Bookmark

Implication

Population-based outcomes reveal survival differences by estrogen receptor levels in HER2-negative breast cancer, indicating treatment implications.

Abstract PS2-06-15: Population-based outcomes and patterns of care for patients with stage I-III, HER2-negative breast cancer, by estrogen receptor expression levels: a high-resolution study

Key Points

Discussion

Implication

Cite This Study

Abstract PS2-06-15: Population-based outcomes and patterns of care for patients with stage I-III, HER2-negative breast cancer, by estrogen receptor expression levels: a high-resolution study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider